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Abstract
Background: In developed countries, tuberculosis is considered a disease with little loss of Quality-Adjusted Life Years
(QALYs). Tuberculosis treatment is predominantly ambulatory and death from tuberculosis is rare. Research has shown that
there are chronic pulmonary sequelae in a majority of patients who have completed treatment for pulmonary tuberculosis
(PTB). This and other health effects of tuberculosis have not been considered in QALY calculations. Consequently both the
burden of tuberculosis on the individual and the value of tuberculosis prevention to society are underestimated. We
estimated QALYs lost to pulmonary TB patients from all known sources, and estimated health loss to prevalent TB disease.
Methodology/Principal Findings: We calculated values for health during illness and treatment, pulmonary impairment after
tuberculosis (PIAT), death rates, years-of-life-lost to death, and normal population health. We then compared the lifetime
expected QALYs for a cohort of tuberculosis patients with that expected for comparison populations with latent
tuberculosis infection and without tuberculosis infection. Persons with culture-confirmed tuberculosis accrued fewer
lifetime QALYs than those without tuberculosis. Acute tuberculosis morbidity cost 0.046 QALYs (4% of total) per individual.
Chronic morbidity accounted for an average of 0.96 QALYs (78% of total). Mortality accounted for 0.22 QALYs lost (18% of
total). The net benefit to society of averting one case of PTB was about 1.4 QALYs.
Conclusions/Significance: Tuberculosis, a preventable disease, results in QALYs lost owing to illness, impairment, and
death. The majority of QALYs lost from tuberculosis resulted from impairment after microbiologic cure. Successful TB
prevention efforts yield more health quality than previously thought and should be given high priority by health policy
makers. (Refer to Abstracto S1 for Spanish language abstract)
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procedures) [5,6]. Ideally, the use of such measures enables policy
makers to improve economic efficiency by directing resources to
activities that yield the greatest health effect per unit of cost. Further,
complete and accurate estimations of health effects require that
health outcomes be fully measured; this includes QALYs.
In the past, TB health effects have not been fully measured. In
low-incidence areas—while empirically recognized as an important
public health problem—TB is not considered to result in substantial
loss of quality of life. TB is curable, and with a relatively short, welltolerated, and inexpensive treatment it has relatively low mortality
rates in the developed world [7]. As a result, most TB patients
experience limited illness under an ambulatory course of treatment.
In these circumstances, QALYs lost to acute illness and ambulatory
treatments are minimal. So, it has been argued that TB cure may be
substituted for prevention as an efficient policy option when the cost
to prevent a TB case exceeds the cost of its cure [8,9]. However, this
judgment should be made only when benefits are estimated,
including the relevant cost for the value of social benefits and using
appropriate discounting. In fact, all costs associated with TB have
not been measured, and current policy judgments are not
completely informed.

Introduction
Paradoxically, success in TB prevention and control can result
in impediments that threaten elimination efforts [1]. Historically,
as incidence rates fell, funding for TB prevention and control was
reduced and costs—per TB case averted—rose. Increasing TB
costs compromised the ability of public health authorities to justify
TB prevention activities for other public health programs. As a
result, TB managers experienced increased pressure to justify
support of the TB public health practice infrastructure. And we
know now, that past failure to maintain support for TB public
health practice infrastructure leads to TB resurgence [2–4].
The appropriate use of limited government resources requires
accountability for health effects (i.e., reduction of both morbidity
and mortality and of health disparities). The Quality-Adjusted Life
Year (QALY) is a common measure for comparing health effects
between interventions. This measure represents the relative value of
a year-of-life after weighting for quality effects [5]. Scaled between 0
(worst health) and 1 (best health), QALYs allow broad economic
comparisons between widely disparate outcomes (e.g., highway
building, OSHA regulations, public health programs, medical
PLoS ONE | www.plosone.org
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ment after cure, and death resulting from TB are important
components of the full cost to society [12–14].
We estimated societal QALYs lost to TB. Our analyses included
studies of the health effects of acute illness, treatment, pulmonary
impairment after tuberculosis (PIAT), and death, enabling a more
nearly complete estimate of the effects of TB to society.

Table 1. Characteristics of patients treated for pulmonary
tuberculosis (cases) and LTBI (comparison), 2002, Tarrant
County, Texas [10].

Characteristics

Cases
(N = 107) (%)

Comparison
(N = 210) (%)

p-value

Male

74(69)

111(53)

0.005**

Caucasian

25(23)

47(22)

0.889

Hispanic

29(27)

55(26)

0.943

African-American

23(22)

55(26)

0.407

AAIO

30(28)

53(25)

0.523

Ever smoked

61(57)

107(51)

0.217

Ever used crack cocaine

21(20)

36(17)

0.395

Occupational pulmonary risk

6(6)

14(7)

0.834

US-born

55(51)

111(53)

0.831

HIV positive

15(14)

15(7)

0.186

Not Done
Pulmonary impairment

Methods
We estimated the lifetime QALYs for individual TB patients
with culture-confirmed pulmonary disease and the aggregated
QALYs lost to prevalent TB disease in Tarrant County, Texas,
during 2002 [10,11]. We based estimates in part on published data
from cohorts with tuberculosis and latent tuberculosis infection
(LTBI) [10,11]. Cohort demographics and measures of health after
treatment were taken from the same studies (table 1) [10,11].
Values for health during illness and treatment, death rates, years of
life lost to death, and normal population health were taken from
previously published sources (table 2). A decision model was
designed using TreeAge Pro 2005 (1075 Main Street, Williamstown, MA 01267) for each of three states: normal health; latent
tuberculosis infection; and culture confirmed tuberculosis. This
model, along with other calculations to be described later, was
used to derive and compare estimates of the lifetime expected
QALYs for each of the three states.

24(11)
63(59)

41(20)

Mean (SD)

Mean (SD)

Age (years)

47(15)

41(15)

0.003##

BMI

23.75(4.98)

27.66(5.78)

,0.001##

,0.001**

Height (in)

67(4)

66(4)

0.163

Literature Reviewed

(Smoking) pack-years

12.01(18.24)

7.24(14.36)

0.011##

FVC (% predicted)

82.77(24.89)

95.51(19.49)

,0.001##

FEV1 (% predicted)

77.77(27.37)

95.43(19.48)

,0.001##

We searched OVID from 1950 to 2007 by combining keyword
‘‘tuberculosis’’ with each of the modifiers ‘‘quality-adjusted life
years,’’ ‘‘health status,’’ ‘‘disability,’’ ‘‘cost of illness,’’ and
‘‘disability-adjusted life years.’’ The search was limited to the
English language, full-text results, and we reviewed all previously
reported studies of the health status of persons with PTB. We found
no societal estimates of health quality lost to TB in this search.

FEV1/FVC (% predicted)

76.07(13.34)

83.97(7.85)

,0.001##

FEF 25–75 (% predicted)

72.68(41.45)

98.61(31.79)

,0.001##

Table used with permission.
Abbreviations: AAIO-Asians, Africans, Indian, Other; FVC-Forced Vital Capacity;
FEV1-Forced Expiratory Volume in One Second; FEF 25-75-Mid Forced
Expiratory Flow.
**
p,0.05 based on Pearson Chi-square.
##
t-test.
doi:10.1371/journal.pone.0005080.t001

Weighting Effects of TB
Weights giving the health effects of time spent with acute illness
and the effect of chemotherapy for the treatment of TB, including
adverse drug interactions, have been estimated, as have health
state valuations for geographic regions and average losses due to
death during acute illness (table 2) [15–19]. Pulmonary impairment after TB (PIAT) is a chronic sequela, and its health effect has
been identified but not weighted [10,11]. The health effect for the
sequelae of TB was estimated by combining studies of PIAT with
the American Medical Association’s (AMA) pulmonary grading
criteria to determine the degree of impairment. Impairment was

Although many TB health effects are well categorized, key gaps
do exist. For example, we recognized that some TB patients with
microbiologically cured disease do become disabled, but the effect
of this chronic morbidity has not been measured [10,11]. Further,
measures of acute TB illness and treatment, continuing impair-

Table 2. Values and weights used in the estimation of health quality lost, 2002, Tarrant County, Texas.

Values

Weight

Source

Health state valuation weight for illness, convalescence, and treatment: nonfatal TB

0.9

Mauchand, 1999

Health weight s/p pulmonary tuberculosis, no identified pulmonary impairment*

0.921

Pasipanodya, 2007

Health weight s/p pulmonary tuberculosis, mild pulmonary impairment*

0.837

Pasipanodya, 2007

Health weight s/p pulmonary tuberculosis, moderate pulmonary impairment*

0.81

Pasipanodya, 2007

Health weight s/p PTB patient, severe pulmonary impairment*

0.694

Pasipanodya, 2007

Average health weight s/p PTB, all survivors*

0.86

Pasipanodya, 2007

Baseline health state valuation adjusted matched to cohort demographics

0.89

WHO, 2003

Years of life lost to tuberculosis death (in hospital)

16.6

Hansel, 2004; CDC, 2002

TB death rate

0.047

CDC, 2005

doi:10.1371/journal.pone.0005080.t002
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multiplied by the number of years spent in that state; then we
summed over the expected natural life. For patients with
microbiologically cured PTB, the baseline was adjusted to reflect
health quality lost to illness, treatment, and impairment. One-time
quality losses to acute illness and TB treatment (QLTBT) were then
subtracted. Weighting for the health quality effect of pulmonary
impairment after TB (QPIAT) began at its identification and
continued for subsequent expected years of life. This expression
took the form (BHQ*time in state*QPIAT) - QLTBT = lifetime
QALYs for an individual status post PTB. To estimate the QALYs
lost to all patients with PTB, the same formula was used but
included one-time losses for death during acute illness.

graded as none, mild, moderate, or severe [10,20–22]. Grades of
impairment were matched with quantitative measures of health
quality, measured by the St. George’s Respiratory Questionnaire
(SGRQ) [11]. The average health weight for each grade of
impairment was calculated as the percentage difference in SGRQ
score from that found in persons with similar risk factors, and a
weighted average health weight for all pulmonary tuberculosis
patients was calculated.

Sources of Health Lost
We assumed that differences in the cumulative expected QALYs
lost by cohorts with and without TB were due to acute illness and
treatment, chronic health loss (impairment) after treatment, and
death. All individual and cohort demographics were based on 107
PTB patients participating in two Tarrant County studies (table 1).
Baseline health state valuation was then adjusted to age, sex, and
region [17–19].

Statistical Analyses
We used SPSS, version 11.0 for Windows (SPSS Inc. 233 S.
Wacker Drive, 11th floor, Chicago, IL 60606-6307) to perform
statistical calculations. Significant differences between groups were
determined by using the Student t-test and the x2 test. Calculations
relating to health quality, discounting, and weighting were
performed using Microsoft Excel 2002 (Microsoft Corporation,
Redmond, WA). QALYs were reported as net of social discount
rates that were varied from 3%–8% per annum for predicted the
lifespan [26–28]. Discounting captured the inter-temporal opportunity cost-of-capital and the rate-of-time preference for the
present over the future. Unless otherwise stated, findings were
reported net of a 3% social discount rate.

QALYs Lost Owing to Acute Illness and Treatment
The duration of acute illness and treatment were conservatively
estimated as six months, and the outcome is assumed to be cure or
death. Time spent ill and in treatment was multiplied by the
baseline health valuation for each individual and the weight for
illness and ambulatory treatment. The total number of QALYs
that accrued to the cohort as a unit during that time is expressed as
a sum for the cohort and as an average for individual members of
the cohort. The QALYs lost to TB during this time is assumed to
be the difference between these values and those obtained from the
same groups without weighting for illness and treatment.

Results
We estimated the health quality of the entire cohort of 107 PTB
patients. Pulmonary function tests showed that 63 (58.9%) of PTB
patients had pulmonary impairment as defined by the AMA
(table 2). Thirty-seven (34.6%) patients suffered mild; 15 (14.0%)
moderate; and 11 (10.3%) suffered severe impairment (table 3).
Forty-one of 210 (19.5%) patients with LTBI had some pulmonary
impairment. The average severity of impairment was less in those
patients with LTBI, with 35 (16.7%) having mild; 5 (2.4%)
moderate; and 1 (0.5%) patient suffering severe pulmonary
impairment (table 3).

QALYs Lost Owing to Impairment
We assumed that pulmonary function in PTB patients after 20
weeks of treatment would remain stable for the remainder of the
patient’s life [23–25]. We also assumed that health lost following
treatment would continue throughout the patient’s lifetime. To
estimate the years lived with disability, we used life tables adjusted
for sex, age, and geographic region, and we estimated the years of
life lived from the time of microbiologic cure to predicted death
[19]. Time spent from the end of treatment until death was
multiplied by the baseline health valuation and the weight for each
patient’s impairment. Total QALYs lost to the cohort as a whole
during that time was expressed as a sum for the cohort and as an
average for individual members of the cohort. QALYs lost to PTB
during this time were assumed to be the difference in total lifetime
QALYs expected if illness had not occurred.

QALYs Lost to Acute Illness and Treatment
For the entire cohort of 107 PTB patients, we estimated that
acute illness and treatment resulted in a total of 5.35 QALYs lost.
Each individual PTB patient averaged a loss of 0.046 QALYs
prior to clinical cure (table 4).

QALYs Lost to Impairment
QALYs Lost to Death

We estimated that, following therapy, the entire PTB cohort
had lost a net total of 102.73 QALYs. Averaged across the PTB
cohort, individuals would lose a net total 0.96 QALYs (table 4).

We assumed that QALYs lost to death began to accrue from
before or during acute illness. However data related to deaths before
and after enrollment were not collected for this cohort [10]. We
therefore estimated cohort deaths, based upon national data [18].
QALYs lost to death from TB were estimated based on prior reports
giving the average age and the sex of persons who had died from
acute TB [16,19]. We adjusted life tables for sex, age, and geographic
region and used these to estimate years of life remaining until
expected natural death [19]. QALYs lost to death from TB were then
estimated as the difference in total lifetime QALYs expected had
death not occurred. We did not include an estimation of QALYs lost
owing to excessive deaths following completion of treatment.

QALYs Lost to Death
Assuming an average TB death rate of 4.5%, we estimated that
5 TB patients would die prior to entering the cohort. These deaths
would then account for a total loss of 69.6 undiscounted or 24.30
discounted QALYs (table 4). Every individual TB death resulted in
a net loss of 8.52 QALYs (table 4).

Lifetime expected QALYs
We estimated the lifetime expected QALYs for each group
(table 5). Normal populations (weighted to the age and
demographics of the study cohort with a history of PTB), had a
lifetime expectation of 69.11 QALYs. We predicted that cohort
members with LTBI could expect 67.43 QALYs; and that those

Health Quality Calculations
We estimated lifetime health quality for persons without TB by
calculating the baseline health quality (BHQ) for an age range
PLoS ONE | www.plosone.org
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Table 3. Proportion of pulmonary impairments among pulmonary tuberculosis (cases) and control cohorts{, 2002, Tarrant County,
Texas.

Impairment{

Cases

n

Controls

all cases

male

female
%

n

all controls

male
%

n

%

female

n

%

n

%

n

%
0.8

None

25

0.34

18

0.53

43

0.4

89

0.81

77

0.79

166

Mild

27

0.37

10

0.29

37

0.35

19

0.17

16

0.16

35

0.17

Moderate

13

0.18

2

0.06

15

0.14

2

0.02

3

0.03

5

0.02

Severe

8

0.11

4

0.12

12

0.11

0

0

1

0.01

1

0

total

73

1

34

1

107

1

110

1

97

1

207

1

{

Differences in proportion significant at 0.05 level.
Impairment level defined as ,10% difference from normative = no impairment; 10–25% = mild; 26–50% = moderate; 51–100% = severe.
doi:10.1371/journal.pone.0005080.t003
{

accrue to patients that acquired PTB than those with LTBI. This
measure reflects the savings possible through prevention of one
case of PTB.
Sensitivity analyses of discount rates gave QALY loss from TB
morbidity and mortality a range from 3.3 at 0% discount to 0.35
at an 8% discount per annum.

with treated PTB could expect 64.68 QALYs over their life spans
(table 5). We predicted that persons with LTBI could expect 1.69
fewer undiscounted QALYs than persons in the normal population. We predicted that persons with a history of PTB could expect
4.43 fewer QALYs than persons in a normal population and 2.75
fewer QALYs than those in the LTBI group (table 5). From the
time of cure to their expected death, patients with a history of PTB
can expect an average of 0.98 QALYs less than the patients in the
LTBI group.
For patients diagnosed with PTB during the study period, we
estimated an expected difference of 128.9 fewer lifetime QALYs
from the same cohort weighted to reflect health loss of persons
with LTBI. Illness and treatment accounted for 1.5%; death for
18.9%; and PIAT for 79.8% of the total QALY difference (table 4).
On average, an individual difference of 1.2 net QALYs was lost
between those who have had PTB and those without (but with
similar risks). The greatest share of this difference—0.96
QALYs—came from disability after successful treatment. A total
average difference of 1.4 fewer discounted QALYs was expected to

Discussion
In this study, we analyzed—for the first time—the health quality
loss related to PTB. We estimated the total QALYs lost to illness,
treatment, pulmonary sequelae, and death related to PTB. We
compared the expected lifetime QALYs for patients with treated
PTB to that expected to accrue to a normal population, weighted
to the age, sex, and location of the cohorts studied; and to QALYs
expected for a population with LTBI. Although patients with
LTBI share many risk factors with those having PTB, they do not
experience acute disease and its associated effects. We estimated
an average of 69.11, 67.43, and 64.68 lifetime QALYs would
accrue to normal, LTBI, and PTB populations, respectively. These
data show that, on average, persons microbiologically cured of TB
have suffered an important, preventable health loss. Our data also
show that most health losses from TB occur after microbiologic
cure of disease; such losses have previously been unmeasured. The
net benefit of averting one case of PTB is at least 1.4 QALYs.
Further, these data illustrate that successful treatment of LTBI
yields substantially more population health than previously
recognized.
While PIAT is a chronic common sequela of PTB, we found no
prior estimates of health lost to PTB that includes it. We estimated
that PIAT accounts for a difference of 0.96 fewer QALYs in
persons treated for PTB when compared to persons with similar
risks. QALYs lost related to PIAT comprise 80% of the total
QALYs difference between groups. These data demonstrate that
previous studies of health outcomes of PTB have considerably
underestimated the full societal effects of PTB.
These data also suggest that treatment of LTBI has important
benefits not considered in the design of the current treatment
guidelines. The knowledge that chronic PTB sequelae occur
frequently despite successful treatment of PTB may influence
clinicians to recommend treatment of LTBI with greater
frequency. In addition, patient acceptance of LTBI treatment
may be enhanced by the potential benefit of preventing chronic
lung disease. The resulting health benefits may be substantial; we
found that a history of PTB yields a health weight of 0.857, an

Table 4. Quality-adjusted life years lost associated with
pulmonary tuberculosis, 2002, Tarrant County, Texas.

Source

Gross

Net 3% Discount

QALY losses to cohort
TB death*

69.6

24.3

Acute illness/treatment*

5.35

n/a

Disability

294.25

102.73

Total QALY loss to cohort*

369.2

128.90***

QALY losses to individuals
Total per TB patient*

3.3

1.39***

Average loss prior to clinical cure per pt

0.046

n/a

Average loss to death*

0.621

0.38

Total per PTB survivor**

2.8

0.98

Average loss to disability d/t PTB

2.75

0.96

Estimated QALYs lost to TB death, per death

13.92

8.52

*

N = 112, assumes 5 deaths prior to completion of treatment.
N = 107.
Discounting considers: no discount for acute illness/treatment; 16.6 years for
early death, and 35.6 years to expected natural death for survivors.
doi:10.1371/journal.pone.0005080.t004
**

***
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Table 5. Expected lifetime QALYs lost, by condition, Tarrant County, Texas, 2002.

Condition

%
normal

QALYs

QALY difference
from normal

QALY difference from
LTBI

Population normal *

69.11

100%

0

n/a

Normal+LTBI

67.43

97.56%

1.69

0

Normal+microbiologically-cured PTB**

64.68

93.59%

4.43

2.75

*

Expected, weighted to sex/age of cohort.
Estimates based on survivors only.
doi:10.1371/journal.pone.0005080.t005
**

spread across long periods. But the discounting of health relies on
the assumption that there is preference for health in the present
over the future, a presumption that is supported by observations of
behaviors from smoking to dietary habits [26–28]. When discount
rates are higher or when benefits occur far in the future, the
present value of future savings is lower. The present value of
Quality-Adjusted Life Years in this analysis remains substantial
even at a discount rate of 8% over almost 36 years, the average
expected years of life remaining for the cohort and the longest
duration tested, implying that current investments in prevention
can yield an economic return even far in the future. The Tarrant
County pulmonary studies occurred only with patients who had
received at least 20 weeks of treatment, so it is unknown how many
members of the cohort died before that point. To estimate this
number, we used a hypothetical death toll based on the known
national death rate. This may not reflect the actual number of
deaths in Tarrant County during this time.
Excessive deaths soon after treatments have been reported
before now, but estimating such numbers is difficult, so we did not
include such estimates in these analyses [34–36]. There have been
no long-term studies of mortality among PTB patients. However,
lung injury owing to other illnesses is associated with higher
mortality rates [37–39]. Studies of the effect of pulmonary
impairment on mortality have found significantly increased risk
of death for those with moderate or severe impairment (1.6 and
2.7 hazard ratios, respectively). It is plausible that the cohort in this
study would suffer similar mortality effects from PIAT [40].

effect far greater than that reported for many chronic conditions
(table 6) [13,29,30]. For population health, QALYs lost to
survivors with pulmonary impairment are 4.4 times greater than
QALYs lost to PTB mortality.
These data demonstrate that the treatment of LTBI has been
undervalued in the past and that future LTBI treatment guidelines
should include consideration of the benefit of disability prevention
[31]. This may result in recommending treatment of LTBI in
persons currently considered at lower risk for progressing to TB.
These data also have implications for global health policy. Most
PTB cases occur outside the United States, many in economies
with insufficient medical infrastructure [32]. In the population
studied, the burden of disability begins at midlife and continues
until death, corresponding not only with peak earning years but
also during a period of child bearing and rearing and elder care
(figure 1) [33]. By addressing an important, preventable cause of
disability in these populations through strengthening TB prevention programs, it may be possible to effect significant economic
and social gains as well as gains to individual health.
The discounting of future health benefits is controversial [26–
28]. Discounting the monetary value of QALYs is well accepted
and expected for studies where cost and health outcomes are
Table 6. Relative effect of chronic illness on individuals{,
Tarrant County, Texas, 2002.

Condition

Weight

Alcohol or drug related problems

0.768

Anxiety/depression

0.791

Other health problems

0.807

Diabetes

0.835

Arms, legs hands, feet, back or neck

0.841

Epilepsy

0.841

Stomach/liver/kidneys

0.851

Chest, breathing problems, asthma, bronchitis

0.857

Microbiologically cured Pulmonary Tuberculosis{

0.86

Heart, blood problems, or circulation

0.875

Migraine or frequent headaches

0.934

Difficulty in seeing

0.938

Difficulty in hearing

0.962

Skin conditions/allergies

0.966

Figure 1. By decade of life and cohort, the annual quality of
life, 2002, Tarrant County, Texas. PTB = Pulmonary tuberculosis,
n = 107. Comparison = control group with similar pulmonary risk factors,
n = 210. Avg. U.S. population weighted to sex and demographic mix
found in cohort.
doi:10.1371/journal.pone.0005080.g001

{

Adapted with permission from: Happiness Quantified, Van Praag, Ferrer-iCarbonell 2004 (based on self-reported chronic conditions in Britain and selfassessment of effects).
{
As found, survivors of TB completing standard therapy.
doi:10.1371/journal.pone.0005080.t006
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Omitting the possibility of an increase of mortality in patients
cured of TB might lead to an underestimate of QALYs lost to
PTB. This, however, would result only in a change of the
magnitude, not the direction, of our findings.
These measurements may not capture all health quality loss, as
survivors of acute respiratory illness have been found to suffer
impairment in general mood, cognition, and social functioning, as
well as respiratory symptoms. Extra-pulmonary TB may also cause
impairment through its effects on the brain and other organs [37–
40]. Basing our estimates on the expected natural life of a normal
cohort and not considering unknown factors such as possibly
excessive risk of death, might underestimate the differences in
QALYs lost. This makes our results a conservative estimate.
These findings give insight into the relative efficiencies of
emerging technologies related to TB. Currently, several interventions are close to implementation. These technologies include
those that shorten diagnosis and treatment of LTBI such as
gamma interferon release assays for diagnosis, and isoniazid and
rifapentine for treatment. Similarly moxifloxacin containing
regimes shorten treatment of active TB. Our data show that any
interventions resulting in more persons completing LTBI therapy
will save 1.39 QALYs per case of TB averted; a strong argument
for expansion of groups and age ranges considered appropriate for
prophylactic treatment of LTBI. In contrast, interventions for
shortening treatment of TB would result in little QALY savings.
For example, reducing the duration of treatment for cure by 50%
saves only 0.023 QALYs per illness. In addition, shorter treatment

will not reduce the chronic pulmonary impairment associated with
TB [10,34]. These data illustrate that the greatest health savings
will be achieved through strategies to prevent TB from developing,
rather than strategies to shorten treatment once it has developed.
TB results in QALY loss because of illness, chronic impairment,
and death—yet TB is a preventable disease. The current TB
elimination strategy in low-incidence areas emphasizes case
prevention through treatment of LTBI, but does not consider
the value of potential savings from preventing chronic impairment
in treatment recommendations [41–43]. Recognition of these
benefits of treatment of LTBI may result in a number of changes.
These changes include improved patient and clinician acceptance
of LTBI therapy and expanding the population for whom LTBI
treatment is recommended. In addition, these data provide
additional rationale for support of TB control measures.
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